Cases of ALK-rearranged lung cancer with 5-year progression-free survival with crizotinib as initial precision therapy

Ítems similars

• Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% expression in lung adenocarcinoma
  per: Rangachari, Deepa, et al.
  Publicat: (2017)
• Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer
  per: Sehgal, Kartik, et al.
  Publicat: (2018)
• Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation
  per: Jorge, Susan E., et al.
  Publicat: (2015)
• Detection of crizotinib-sensitive lung adenocarcinomas with MET, ALK and ROS1 genomic alterations via comprehensive genomic profiling
  per: Le, Xiuning, et al.
  Publicat: (2015)
• De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers
  per: Lucena-Araujo, Antonio R., et al.
  Publicat: (2016)